Free Trial
→ Democrats can stall every bill. They can’t stop this Trump order. (From Priority Gold) (Ad)tc pixel
OTCMKTS:FSNUY

Fresenius SE & Co. Q2 2025 Earnings Results & Report

Fresenius SE & Co. logo
$14.83 +0.11 (+0.77%)
As of 10:57 AM Eastern

Fresenius SE & Co. beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 6, 2025. The company reported EPS of $0.24 versus the $0.2182 consensus estimate, while revenue of $6.48 billion topped the $5.83 billion estimate by $648.79 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens

Fresenius SE & Co. EPS Results

Actual EPS
$0.24
Consensus EPS
$0.2182
Beat/Miss
Beat by +$0.0218
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 6 quarters

Fresenius SE & Co. Revenue Results

Actual Revenue
$6.48 billion
Expected Revenue
$5.83 billion
Beat/Miss
Beat by +$648.79 million
YoY Revenue Growth
N/A

Conference Call Resources

Fresenius SE & Co. Q2 2025 Earnings FAQ

Fresenius SE & Co. (OTCMKTS:FSNUY) reported earnings of $0.24 per share for Q2 2025, beating the consensus estimate of $0.2182. The report was announced on Wednesday, August 6, 2025.

Fresenius SE & Co. reported revenue of $6.48 billion for Q2 2025, against a consensus estimate of $5.83 billion.

Fresenius SE & Co. Earnings Headlines

Fresenius plans to sell around 13.4 million FMC shares
November 11 at 2:40 PM  |  marketscreener.comM
Fresenius SE & Co. KGaA (FSNUY) Q3 2026 Earnings Call Transcript
November 4, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4962198-fresenius-se-and-co-kgaa-fsnuy-q3-2026-earnings-call-transcript
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
November 12 at 1:00 AM  |  Weiss Ratings (Ad)
Fresenius expands biosimilar business through partnership with China's WuXi
November 3, 2026  |  marketscreener.comM
Fresenius, WuXi Enter Development Agreement To Expand Biosimilars Pipeline
November 3, 2026  |  rttnews.comhttps://www.rttnews.com/3706985/fresenius-wuxi-enter-development-agreement-to-expand-biosimilars-pipeline.aspx
Jefferies leaves Fresenius SE at 'Buy', target €55
November 3, 2026  |  marketscreener.comM
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a German healthcare group headquartered in Bad Homburg. Its businesses include Fresenius Kabi, which supplies medicines, clinical nutrition, infusion therapies and medical technologies, and Fresenius Helios, which operates hospitals in Germany and Spain.

Fresenius Kabi serves healthcare providers around the world, while Helios focuses on hospital and healthcare services in Europe. The group traces its origins to a pharmacy in Frankfurt acquired by pharmacist Eduard Fresenius in 1912.

Michael Sen has served as Fresenius’s chief executive officer since 2022. Through its businesses, the company provides products and services across areas including hospital care, pharmaceuticals and medical technology.

View Fresenius SE & Co. Profile
Earnings Tools